Last reviewed · How we verify
MIL116
At a glance
| Generic name | MIL116 |
|---|---|
| Sponsor | Beijing Mabworks Biotech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1 Study of CLYM116 in Normal Healthy Volunteers (PHASE1)
- A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MIL116 CI brief — competitive landscape report
- MIL116 updates RSS · CI watch RSS
- Beijing Mabworks Biotech Co., Ltd. portfolio CI